What Next for Jazz Pharmaceuticals Plc – Ordinary Shares (NASDAQ:JAZZ) Stock After Increase in Shorted Shares?

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Logo

Investors sentiment decreased to 1.17 in 2019 Q2. Its down 0.32, from 1.49 in 2019Q1. It worsened, as 36 investors sold Jazz Pharmaceuticals plc shares while 105 reduced holdings. 52 funds opened positions while 113 raised stakes. 50.63 million shares or 4.18% more from 48.59 million shares in 2019Q1 were reported.
Blackrock Incorporated stated it has 0.02% in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Sei Invs reported 61,647 shares. Riverhead Capital Ltd Liability Com holds 0.13% or 24,260 shares. Sarissa Capital Mngmt L P has invested 3.49% of its portfolio in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Gateway Investment Advisers Ltd Limited Liability Company reported 0.04% stake. Pggm Invests reported 51,110 shares. Andra Ap holds 38,600 shares. Peoples stated it has 36 shares. Alliancebernstein Ltd Partnership owns 34,123 shares. Stifel Financial Corp stated it has 38,404 shares. National Bank has 0% invested in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Eqis Cap Management holds 12,477 shares. Segall Bryant & Hamill Ltd invested in 0% or 2,295 shares. Federated Pa holds 127,377 shares or 0.04% of its portfolio. Amp Cap Invsts Limited holds 0.03% in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) or 33,889 shares.

The stock of Jazz Pharmaceuticals Plc – Ordinary Shares (NASDAQ:JAZZ) registered an increase of 10.97% in short interest. JAZZ’s total short interest was 2.24M shares in September as published by FINRA. Its up 10.97% from 2.02M shares, reported previously. With 499,000 shares average volume, it will take short sellers 5 days to cover their JAZZ’s short positions. The short interest to Jazz Pharmaceuticals Plc – Ordinary Shares’s float is 4.08%.

The stock decreased 0.03% or $0.04 during the last trading session, reaching $131.41. About 330,700 shares traded. Jazz Pharmaceuticals plc (NASDAQ:JAZZ) has declined 19.23% since September 13, 2018 and is downtrending. It has underperformed by 19.23% the S&P500.

Jazz Pharmaceuticals Public Limited Company, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has market cap of $7.44 billion. The firm has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. It has a 11.92 P/E ratio. It markets Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia (ALL); Defitelio for the treatment and prevention of severe hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Prialt, an intrathecally administered infusion of ziconotide for the management of severe chronic pain.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Ratings Coverage

Among 8 analysts covering Jazz Pharmaceuticals (NASDAQ:JAZZ), 6 have Buy rating, 0 Sell and 2 Hold. Therefore 75% are positive. Jazz Pharmaceuticals has $20800 highest and $14200 lowest target. $168.25’s average target is 28.03% above currents $131.41 stock price. Jazz Pharmaceuticals had 8 analyst reports since March 18, 2019 according to SRatingsIntel. Wells Fargo maintained it with “Buy” rating and $162 target in Tuesday, March 19 report. The rating was maintained by BMO Capital Markets on Wednesday, May 8 with “Outperform”. The company was maintained on Monday, March 18 by RBC Capital Markets. The rating was downgraded by Piper Jaffray to “Neutral” on Wednesday, August 21. SunTrust initiated it with “Buy” rating and $163 target in Tuesday, March 19 report. The firm has “Neutral” rating by Mizuho given on Wednesday, May 8. Oppenheimer maintained Jazz Pharmaceuticals plc (NASDAQ:JAZZ) on Thursday, March 21 with “Buy” rating.

More notable recent Jazz Pharmaceuticals plc (NASDAQ:JAZZ) news were published by: Seekingalpha.com which released: “Piper softens view on Jazz Pharma in premarket analyst action – Seeking Alpha” on August 21, 2019, also Finance.Yahoo.com with their article: “What Should Investors Know About Jazz Pharmaceuticals plc’s (NASDAQ:JAZZ) Earnings Outlook? – Yahoo Finance” published on May 06, 2019, 247Wallst.com published: “Top Analyst Upgrades and Downgrades: Baidu, BP, Ciena, Chevron, Cree, Exxon, Home Depot, Medtronic, Nvidia, Urban Outfitters and More – 24/7 Wall St.” on August 21, 2019. More interesting news about Jazz Pharmaceuticals plc (NASDAQ:JAZZ) were released by: 247Wallst.com and their article: “Vertex Pharmaceuticals and Other Biotech Stocks With Recent Golden Crosses – 24/7 Wall St.” published on August 26, 2019 as well as Nasdaq.com‘s news article titled: “JAZZ vs. ZTS: Which Stock Is the Better Value Option? – Nasdaq” with publication date: April 16, 2019.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.